Suppr超能文献

[改善稳定型心绞痛患者治疗效果的新机遇]

[New opportunities to improve the treatment effectiveness of patients with stable angina].

作者信息

Grigoryeva N Yu, Vilkova O E, Samolyuk M O, Kolosova K S

机构信息

Federal State Budgetary Educational Institution of Higher Education «Privolzhsky Research Medical University» of the Ministry of Health of the Russian Federation, Nizhny Novgorod.

出版信息

Kardiologiia. 2020 Jul 7;60(6):1135. doi: 10.18087/cardio.2020.6.n1135.

Abstract

Aim To study the antianginal and heart rate slowing effects in patients with stable angina (SA) who failed to achieve the heart rate (HR) goal and were switched from the beta-blocker (BB) metoprolol tartrate to a combination of metoprolol tartrate and ivabradine.Materials and methods The study included 54 patients with SA not higher than functional class (FC) III (35 (64.8 %) men and 19 (35.2 %) women) aged 59 [48; 77] years. Prior to the study start and at 4 and 8 weeks of follow-up, electrocardiography (ECG) and 24-h ECG monitoring (24h-ECGM) were performed for all patients. The follow-up period duration was 8 weeks. The antianginal and heart rate slowing effects of therapy were clinically evaluated by a decrease in frequency of anginal attacks and patients' requirement for nitrates, a decrease in HR, and the effect on 24h-ECGM indexes characterizing myocardial ischemia. At the first stage, all patients were prescribed metoprolol tartrate (Egilok®, Egis, Hungary) 25 mg twice a day. Patients with resting HR still higher than 70 bpm after 4 weeks of treatment were switched from metoprolol tartrate to a fixed ivabradine/metoprolol combination (Implicor®, Servier, France) 5 / 25 mg twice a day. Thus, based on achieving/ non-achieving the HR goal, two groups of patients were formed. Statistical analysis was performed with a STATISTICA 10,0 software package.Results After 4 weeks of therapy with metoprolol tartrate 25 mg twice a day, 18 (33.3%) patients of group 1 achieved the HR goal of 70 bpm, while  36 (66.7%) patients of group 2 did not achieve the goal. For further correction of HR, patients of group 2 were switched from metoprolol tartrate to ivabradine/metoprolol 5 / 25 mg twice a day. After 4 weeks of the ivabradine/metoprolol treatment, 31 (86.1 %) patients achieved the HR goal with median resting HR of 62 [56; 70] bpm. The number of angina attacks decreased from 6 [3; 8] to 2 [1; 3] per week (р<0.001). 24hECGM showed that the mean diurnal HR decreased from 81 [76; 96] to 66 [56; 76] bpm (р<0.001); mean night HR decreased from 69 [73; 80] to 52 [43; 60] bpm (р=0.012); and the ischemic ST segment depression was absent.Conclusion Only 33.3% of patients with stable angina achieved the HR goal on metoprolol tartrate 25 mg twice a day. Supplementing the beta-blocker metoprolol tartrate at the same dose with ivabradine allowed 86.1% of patients to achieve the HR goal and exerted a pronounced anti-anginal effect.

摘要

目的 研究在未达到心率(HR)目标且从β受体阻滞剂(BB)酒石酸美托洛尔转换为酒石酸美托洛尔与伊伐布雷定联合用药的稳定型心绞痛(SA)患者中的抗心绞痛和心率减慢作用。

材料和方法 该研究纳入了54例SA患者,其功能分级(FC)不高于III级(男性35例(64.8%),女性19例(35.2%)),年龄59[48;77]岁。在研究开始前以及随访的第4周和第8周,对所有患者进行心电图(ECG)和24小时动态心电图监测(24h-ECGM)。随访期为8周。通过心绞痛发作频率的降低、患者对硝酸盐的需求降低、心率的降低以及对表征心肌缺血的24h-ECGM指标的影响,对治疗的抗心绞痛和心率减慢作用进行临床评估。在第一阶段,所有患者均被处方酒石酸美托洛尔(Egilok®,Egis,匈牙利)25mg,每日两次。治疗4周后静息心率仍高于70次/分钟的患者从酒石酸美托洛尔转换为固定的伊伐布雷定/美托洛尔组合(Implicor®,Servier,法国)5/25mg,每日两次。因此,根据是否达到HR目标,形成了两组患者。使用STATISTICA 10.0软件包进行统计分析。

结果 每天两次服用25mg酒石酸美托洛尔治疗4周后,第1组18例(33.3%)患者达到了70次/分钟的HR目标,而第2组36例(66.7%)患者未达到该目标。为进一步校正心率,第2组患者从酒石酸美托洛尔转换为每天两次服用5/25mg伊伐布雷定/美托洛尔。伊伐布雷定/美托洛尔治疗4周后,31例(86.1%)患者达到HR目标,静息心率中位数为62[56;70]次/分钟。心绞痛发作次数从每周6[3;8]次减少至2[1;3]次(р<0.001)。24h-ECGM显示,日间平均心率从81[76;96]次/分钟降至66[56;76]次/分钟(р<0.001);夜间平均心率从69[73;80]次/分钟降至52[43;60]次/分钟(р=0.012);且缺血性ST段压低消失。

结论 每天两次服用25mg酒石酸美托洛尔时,仅33.3%的稳定型心绞痛患者达到HR目标。在相同剂量的β受体阻滞剂酒石酸美托洛尔中补充伊伐布雷定可使86.1%的患者达到HR目标,并发挥显著的抗心绞痛作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验